[go: up one dir, main page]

NO20062134L - Fremgangsmater for syntetisering av heteromultimere polypeptider i gjaer ved anvendelse av haploid parrings strategi - Google Patents

Fremgangsmater for syntetisering av heteromultimere polypeptider i gjaer ved anvendelse av haploid parrings strategi

Info

Publication number
NO20062134L
NO20062134L NO20062134A NO20062134A NO20062134L NO 20062134 L NO20062134 L NO 20062134L NO 20062134 A NO20062134 A NO 20062134A NO 20062134 A NO20062134 A NO 20062134A NO 20062134 L NO20062134 L NO 20062134L
Authority
NO
Norway
Prior art keywords
methods
yeast
hapioid
transformed
synthesizing
Prior art date
Application number
NO20062134A
Other languages
English (en)
Inventor
John Latham
Randall Schatzman
Ilya I Tolstorukov
Mark Litton
James Cregg
Original Assignee
Alder Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alder Biopharmaceuticals Inc filed Critical Alder Biopharmaceuticals Inc
Publication of NO20062134L publication Critical patent/NO20062134L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Det tilveiebringes fremgangsmåter for syntese og sekresjon av rekombinante heteromultimere proteiner i paringsdyktig gjær. En første ekspresjonsvektor transformeres inn i en første hapioid celle; og en andre ekspresjonsvektor transformeres inn i en andre hapioid celle. De transformerte hapioide cellene, som hver individuelt syntetiserer et ikke-identisk polypeptid, blir identifisert og deretter genetisk krysset eller fusjonert. De resulterende diploide stammene anvendes for å produsere og sekretere fullstendig sammensatte og biologisk funksjonelle heteromultimere proteiner.
NO20062134A 2003-10-22 2006-05-12 Fremgangsmater for syntetisering av heteromultimere polypeptider i gjaer ved anvendelse av haploid parrings strategi NO20062134L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51387603P 2003-10-22 2003-10-22
PCT/US2004/035302 WO2005040395A1 (en) 2003-10-22 2004-10-22 Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy

Publications (1)

Publication Number Publication Date
NO20062134L true NO20062134L (no) 2006-06-26

Family

ID=34520146

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062134A NO20062134L (no) 2003-10-22 2006-05-12 Fremgangsmater for syntetisering av heteromultimere polypeptider i gjaer ved anvendelse av haploid parrings strategi

Country Status (16)

Country Link
US (7) US8268582B2 (no)
EP (2) EP1678314B1 (no)
JP (3) JP4994038B2 (no)
CN (2) CN101979650B (no)
AU (2) AU2004283299B2 (no)
CA (1) CA2541651C (no)
DK (2) DK1678314T3 (no)
ES (2) ES2393555T3 (no)
HU (1) HUE033349T2 (no)
IL (2) IL174783A (no)
NO (1) NO20062134L (no)
NZ (1) NZ547279A (no)
PL (1) PL1678314T3 (no)
PT (1) PT1678314E (no)
SI (1) SI1678314T1 (no)
WO (1) WO2005040395A1 (no)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9139825B2 (en) 2009-10-30 2015-09-22 Novartis Ag Universal fibronectin type III bottom-side binding domain libraries

Families Citing this family (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE032131T2 (en) 2005-08-31 2017-09-28 Merck Sharp & Dohme Constructed anti-IL-23 antibodies
NZ572807A (en) * 2006-05-19 2011-10-28 Alder Biopharmaceuticals Inc Culture method for obtaining a clonal population of antigen-specific b cells
KR100778219B1 (ko) 2006-08-28 2007-11-29 한국생명공학연구원 교배형 특이적 유전자에 의해 조절되는 반수체 제조용형질전환 효모 균주의 제조
US7795411B2 (en) 2006-10-05 2010-09-14 Fred Hutchinson Cancer Research Center Vectors for expressing in vivo biotinylated recombinant proteins
BRPI0720271A2 (pt) 2006-12-14 2014-01-28 Schering Corp Anticorpo anti-tslp projetado
AU2008216418A1 (en) * 2007-02-09 2008-08-21 Medimmune, Llc Antibody libray display by yeast cell plasma membrane
CN101663320A (zh) 2007-02-23 2010-03-03 先灵公司 工程改造的抗IL-23p19抗体
DK2426144T3 (en) 2007-02-23 2019-01-07 Merck Sharp & Dohme Manipulated Anti-IL-23P19 Antibodies
EP2057194B1 (en) 2007-02-28 2013-03-20 Merck Sharp & Dohme Corp. Engineered anti-il-23r antibodies
US8252286B2 (en) * 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US20100290993A1 (en) * 2007-05-21 2010-11-18 Leon Garcia-Martinez Antibodies to IL-6 and use thereof
KR20100028571A (ko) * 2007-05-21 2010-03-12 앨더 바이오파마슈티컬즈, 인코포레이티드 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US9056905B2 (en) * 2007-05-21 2015-06-16 Alderbio Holdings Llc Antibodies to TNF-α and use thereof
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
JP5898496B2 (ja) 2008-11-25 2016-04-06 アルダーバイオ ホールディングス エルエルシー Ｉｌ−６に対する抗体およびその使用
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
CA3067609A1 (en) 2009-09-03 2011-03-10 Merck Sharp & Dohme Corp. Anti-gitr antibodies
WO2011056772A1 (en) 2009-11-04 2011-05-12 Schering Corporation Engineered anti-tslp antibody
JP5934652B2 (ja) 2009-11-24 2016-06-15 アルダーバイオ ホールディングス エルエルシー Ｉｌ−６に対する抗体およびその使用
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
GB201003701D0 (en) * 2010-03-05 2010-04-21 Cilian Ag System for the expression of a protein
PT2566517T (pt) 2010-05-04 2019-01-24 Five Prime Therapeutics Inc Anticorpos que ligam csf1r
AU2011332810A1 (en) 2010-11-23 2013-06-13 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of oral mucositis
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
CA2821515A1 (en) 2010-12-01 2012-06-07 Alder Biopharmaceuticals, Inc. Anti-ngf compositions and use thereof
WO2012097238A2 (en) 2011-01-14 2012-07-19 Five Prime Therapeutics, Inc. Il-27 antagonists for treating inflammatory diseases
CN103748111B (zh) 2011-05-20 2018-04-27 奥尔德生物控股有限责任公司 抗cgrp组合物及其用途
EP2709662B1 (en) 2011-05-20 2019-07-31 AlderBio Holdings LLC Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
JP6193220B2 (ja) 2011-05-20 2017-09-06 アルダーバイオ・ホールディングズ・エルエルシー 形質転換されたピキア・パストリス（Ｐｉｃｈｉａｐａｓｔｏｒｉｓ）などの微生物における抗体などのマルチサブユニットタンパク質の高純度生産
KR101965461B1 (ko) 2011-05-20 2019-04-04 앨더바이오 홀딩스 엘엘씨 필요한 대상체, 특히 편두통 환자의 광선공포증 또는 광선 혐오증을 예방 또는 억제하기 위한 항-cgrp 항체 및 항체 단편의 용도
KR101978534B1 (ko) * 2011-08-19 2019-08-28 앨더바이오 홀딩스 엘엘씨 변형된 미생물 이를 테면 피치아 파스토리스(pichia pastoris)에서 다수의 아단위 단백질들, 이를 테면 항체의 고역가 및 고순도 생산을 위한 다중-복사체 전략
US10150968B2 (en) 2011-08-19 2018-12-11 Alderbio Holdings Llc Multi-copy strategy for high-titer and high-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
RU2670743C9 (ru) 2012-05-11 2018-12-19 Файв Прайм Терапьютикс, Инк. Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
WO2014004436A2 (en) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Crystalline anti-human il-23 antibodies
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
CN103911371B (zh) * 2013-01-05 2016-05-04 中国科学院微生物研究所 一种酿酒酵母整合型表达载体
US20150366890A1 (en) 2013-02-25 2015-12-24 Trustees Of Boston University Compositions and methods for treating fungal infections
US10202630B2 (en) 2013-03-15 2019-02-12 Alderbio Holdings Llc Temperature shift for high yield expression of polypeptides in yeast and other transformed cells
CA2905531C (en) 2013-03-15 2023-01-03 Alder Biopharmaceuticals, Inc. Antibody purification and purity monitoring
CA2905180C (en) 2013-03-15 2023-03-07 Alder Biopharmaceuticals, Inc. Temperature shift for high yield expression of polypeptides in yeast and other transformed cells
SG10201906172XA (en) 2013-07-03 2019-08-27 Alder Biopharmaceuticals Inc Regulation of glucose metabolism using anti-cgrp antibodies
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
CN105517572B (zh) 2013-07-05 2019-05-31 华盛顿大学商业中心 用于治疗癌症的中和可溶性mic的单克隆抗体
PE20210949A1 (es) 2013-08-01 2021-05-24 Five Prime Therapeutics Inc Anticuerpos anti-fgfr2iiib afucosilados
CN103468595B (zh) * 2013-09-24 2016-01-13 浙江海正药业股份有限公司 表达重组人血白蛋白的酵母菌、其构建方法及应用和表达重组人血白蛋白的方法
CN103710278A (zh) * 2013-12-25 2014-04-09 江南大学 一种低产尿素的工业黄酒酵母代谢工程菌及其构建方法
EP3116957B1 (en) 2014-03-11 2019-06-12 The Chemours Company FC, LLC Tailored dispersion and formation of integrated particle systems via ph responsive groups
EA037561B1 (ru) 2014-06-23 2021-04-14 Файв Прайм Терапьютикс, Инк. Способы лечения заболеваний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
RS61602B1 (sr) 2014-10-29 2021-04-29 Five Prime Therapeutics Inc Kombinovana terapija za kancer
US10626176B2 (en) 2014-10-31 2020-04-21 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind B7-H4
TW201629098A (zh) 2014-12-19 2016-08-16 艾爾德生物製藥股份有限公司 人類化抗 acth 抗體及其用途
HK1245804A1 (zh) 2014-12-22 2018-08-31 Five Prime Therapeutics, Inc. 用於治疗pvns的抗csf1r抗体
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
CN107428833B (zh) 2015-01-16 2021-11-02 朱诺治疗学股份有限公司 Ror1特异性抗体和嵌合抗原受体
RS60614B1 (sr) 2015-03-23 2020-08-31 Jounce Therapeutics Inc Antitela za icos
CN107709365A (zh) 2015-04-13 2018-02-16 戊瑞治疗有限公司 癌症组合疗法
WO2016179194A1 (en) 2015-05-04 2016-11-10 Jounce Therapeutics, Inc. Lilra3 and method of using the same
WO2017019777A1 (en) * 2015-07-27 2017-02-02 Washington University Toolkit for the production of post-translationally modified proteins
US10865394B2 (en) 2015-07-27 2020-12-15 Washington University Toolkit for the production of post-translationally modified proteins
HK1258249A1 (zh) 2015-10-22 2019-11-08 震动疗法股份有限公司 用於测定icos表达的基因标志
TWI791422B (zh) 2015-11-23 2023-02-11 美商戊瑞治療有限公司 用於癌症治療之單獨fgfr2抑制劑或與免疫刺激劑組合
TW201738272A (zh) 2016-04-15 2017-11-01 艾爾德生物製藥股份有限公司 抗ｐａｃａｐ抗體及其用途
BR112019001327A2 (pt) 2016-07-29 2019-04-30 Juno Therapeutics Inc anticorpos anti-idiotípicos e métodos relacionados
MX2019004834A (es) 2016-11-02 2019-06-20 Jounce Therapeutics Inc Anticuerpos de pd-1 y usos de estos.
BR112019013238A2 (pt) 2017-01-20 2020-02-11 Tayu Huaxia Biotech Medical Group Co., Ltd. Anticorpos anti-pd-1 e usos dos mesmos
WO2018187191A1 (en) 2017-04-03 2018-10-11 Jounce Therapeutics, Inc Compositions and methods for the treatment of cancer
ES3041987T3 (en) 2017-05-16 2025-11-17 Five Prime Therapeutics Inc Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
CN111511370A (zh) 2017-11-01 2020-08-07 朱诺治疗学股份有限公司 对b细胞成熟抗原具有特异性的抗体和嵌合抗原受体
JP7447006B2 (ja) 2017-11-01 2024-03-11 ジュノー セラピューティクス インコーポレイテッド Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体
KR102791781B1 (ko) 2017-12-01 2025-04-09 화이자 인코포레이티드 항-cxcr5 항체 및 그의 조성물 및 용도
EP3724225A1 (en) 2017-12-15 2020-10-21 Juno Therapeutics, Inc. Anti-cct5 binding molecules and methods of use thereof
EP3728318A2 (en) 2017-12-22 2020-10-28 Jounce Therapeutics, Inc. Antibodies for lilrb2
EP3774863A1 (en) 2018-03-29 2021-02-17 Pfizer Inc Lfa3 variants and compositions and uses thereof
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
JP2021525806A (ja) 2018-06-01 2021-09-27 タユー ファシャ バイオテック メディカル グループ カンパニー， リミテッド 疾患または状態を処置するための組成物およびそれらの使用
PE20211604A1 (es) 2018-07-09 2021-08-23 Five Prime Therapeutics Inc Anticuerpos de union a ilt4
CN112424231B (zh) 2018-07-19 2022-09-13 大有华夏生物医药集团有限公司 抗pd-1抗体及其剂量和用途
MX2021001703A (es) 2018-08-13 2021-04-19 Inhibrx Inc Polipeptidos de union a ox40 y sus usos.
AU2019336197A1 (en) 2018-09-07 2021-02-18 Pfizer Inc. Anti-avb8 antibodies and compositions and uses thereof
CA3111458A1 (en) 2018-09-10 2020-03-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against cll1 and constructs thereof
WO2020076970A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. B7h3 single domain antibodies and therapeutic compositions thereof
WO2020077257A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
TW202506736A (zh) 2018-10-11 2025-02-16 美商因荷布瑞克斯生物科學公司 5t4單域抗體及其治療性組合物
CA3115089A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
AU2019372331A1 (en) 2018-11-01 2021-05-27 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
AU2019374103A1 (en) 2018-11-01 2021-05-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)
US20220089667A1 (en) 2019-01-07 2022-03-24 Inhibrx, Inc. Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
BR112020018192A2 (pt) 2019-01-08 2021-08-24 H. Lundbeck A/S Tratamento agudo e tratamento rápido de dor de cabeça com o uso de anticorpos anti-cgrp
JP7538130B2 (ja) 2019-01-23 2024-08-21 タユー ファシャ バイオテック メディカル グループ カンパニー， リミテッド 抗ｐｄ－ｌ１ダイアボディおよびその使用
WO2020160050A1 (en) 2019-01-29 2020-08-06 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
EP3938396A1 (en) 2019-03-11 2022-01-19 Jounce Therapeutics, Inc. Anti-icos antibodies for the treatment of cancer
US11560428B2 (en) 2019-05-04 2023-01-24 Inhibrx, Inc. CD33-binding polypeptides and uses thereof
JP7571347B2 (ja) 2019-05-04 2024-10-23 インヒブルクス バイオサイエンシズ インコーポレイテッド ＣＬＥＣ１２ａ結合性ポリペプチド及びその使用
CA3139061A1 (en) 2019-05-04 2020-11-12 Inhibrx, Inc. Cd123-binding polypeptides and uses thereof
CN114787188A (zh) 2019-11-05 2022-07-22 震动疗法股份有限公司 用抗pd-1抗体治疗癌症的方法
KR20220122656A (ko) 2019-12-06 2022-09-02 주노 쎄러퓨티크스 인코퍼레이티드 Ｇｐｒｃ5ｄ-표적화 결합 도메인에 대한 항-이디오타입 항체 및 관련 조성물 및 방법
WO2021113776A1 (en) 2019-12-06 2021-06-10 Juno Therapeutics, Inc. Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods
US20230045791A1 (en) 2020-01-06 2023-02-16 Hifibio (Hk) Limited Anti-tnfr2 antibody and uses thereof
AU2021205143A1 (en) 2020-01-07 2022-07-28 Hifibio, Inc. Anti-Galectin-9 antibody and uses thereof
EP4097129A1 (en) 2020-01-29 2022-12-07 Inhibrx, Inc. Cd28 single domain antibodies and multivalent and multispecific constructs thereof
EP4103285A2 (en) 2020-02-14 2022-12-21 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
EP4112642A4 (en) 2020-02-28 2024-06-26 Shanghai Henlius Biotech, Inc. ANTI-CD137 CONSTRUCTION AND ITS USE
AU2021228078A1 (en) 2020-02-28 2022-09-22 Shanghai Henlius Biotech, Inc. Anti-CD137 constructs, multispecific antibody and uses thereof
AU2020202454A1 (en) 2020-04-06 2021-10-21 H. Lundbeck A/S Treatment of most bothersome symptom (MBS) associated with migraine using anti-CGRP antibodies
AU2021251265A1 (en) 2020-04-10 2022-11-03 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting B-cell maturation antigen
CA3173134A1 (en) 2020-04-20 2021-10-28 Jounce Therapeutics, Inc. Compositions and methods for vaccination and the treatment of infectious diseases
US20230331846A1 (en) 2020-05-04 2023-10-19 Inhibrx, Inc. Canine PD-1-Binding Polypeptides and Uses Thereof
CN116529260A (zh) 2020-06-02 2023-08-01 当康生物技术有限责任公司 抗cd93构建体及其用途
EP4157462A1 (en) 2020-06-02 2023-04-05 Dynamicure Biotechnology LLC Anti-cd93 constructs and uses thereof
WO2022006380A2 (en) 2020-07-02 2022-01-06 Inhibrx, Inc. Polypeptides comprising modified il-2 polypeptides and uses thereof
CA3184940A1 (en) 2020-07-07 2022-01-13 Jennifer Donglan WU Mic antibodies and binding agents and methods of using the same
CA3190328A1 (en) 2020-07-29 2022-02-03 Dynamicure Biotechnology Llc Anti-cd93 constructs and uses thereof
US20230324408A1 (en) 2020-08-05 2023-10-12 Juno Therapeutics, Inc. Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
CA3188996A1 (en) 2020-08-10 2022-02-17 Tengfei XIAO Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8
CN111944708B (zh) * 2020-08-27 2022-04-01 宜宾五粮液股份有限公司 高产乙酸异戊酯的酵母及其应用
CN118146385A (zh) 2020-09-28 2024-06-07 安济盛生物医药有限公司 抗硬骨抑素构建体及其用途
US20240011016A1 (en) * 2020-11-23 2024-01-11 Merck Sharp & Dohme Llc Full-length human immunoglobulin g antibody libraries for surface display and secretion in saccharomyces cerevisiae
US11720540B2 (en) 2020-12-30 2023-08-08 Itron, Inc. Secure blockchain data recovery
WO2022169825A1 (en) 2021-02-03 2022-08-11 Mozart Therapeutics, Inc. Binding agents and methods of using the same
TW202245839A (zh) 2021-02-19 2022-12-01 美商英伊布里克斯公司 Dr5結合多肽之調配物
US20240141048A1 (en) 2021-03-05 2024-05-02 Dynamicure Biotechnology Llc Anti-vista constructs and uses thereof
US20240150466A1 (en) 2021-03-25 2024-05-09 Dynamicure Biotechnology Llc Anti-igfbp7 constructs and uses thereof
AU2022253902A1 (en) 2021-04-10 2023-11-02 Genmab A/S Folr1 binding agents, conjugates thereof and methods of using the same
WO2022226317A1 (en) 2021-04-23 2022-10-27 Profoundbio Us Co. Anti-cd70 antibodies, conjugates thereof and methods of using the same
WO2022241057A1 (en) 2021-05-12 2022-11-17 Applied Biomedical Science Institute Binding polypeptides against sars cov-2 and uses thereof
EP4355785A1 (en) 2021-06-17 2024-04-24 Amberstone Biosciences, Inc. Anti-cd3 constructs and uses thereof
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
EP4359794A4 (en) 2021-07-13 2025-04-16 Keystone Bio, Inc. Diagnostics for porphyromonas gingivalis
EP4373854A1 (en) 2021-07-20 2024-05-29 Inhibrx, Inc. Cd8-binding polypeptides and uses thereof
WO2023004305A1 (en) 2021-07-20 2023-01-26 Inhibrx, Inc. Cd8-targeted modified il-2 polypeptides and uses thereof
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
EP4433096A1 (en) 2021-11-19 2024-09-25 Ardeagen Corporation Gpc3 binding agents, conjugates thereof and methods of using the same
EP4460521A1 (en) 2022-01-05 2024-11-13 Inhibrx Biosciences, Inc. Gamma delta t-cell-binding polypeptides and uses thereof
US20250109203A1 (en) 2022-01-05 2025-04-03 Inhibrx Biosciences, Inc. Gamma Delta T-Cell-Targeted Modified IL-2 Polypeptides and Uses Thereof
KR20240158391A (ko) 2022-02-18 2024-11-04 라쿠텐 메디칼, 인크. 항-프로그래밍된 사멸-리간드 1(pd-l1) 항체 분자, 암호화 폴리뉴클레오티드 및 사용 방법
CA3247628A1 (en) 2022-04-08 2023-10-12 Inhibrx Biosciences, Inc. POLYTHERAPY INCLUDING A DR5 AGONIST AND A PLK1 OR CDK INHIBITOR
EP4519311A1 (en) 2022-05-05 2025-03-12 Inhibrx Biosciences, Inc. Albumin-binding polypeptides and uses thereof
IL316990A (en) 2022-05-23 2025-01-01 Cereius Inc HER2 binding agents and their uses
EP4529455A1 (en) 2022-05-23 2025-04-02 Inhibrx Biosciences, Inc. Dr5 agonist and iap antagonist combination therapy
WO2023235699A1 (en) 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof
IL317523A (en) 2022-06-11 2025-02-01 Inhibrx Biosciences Inc FcRn-binding polypeptides and uses thereof
WO2024006975A1 (en) 2022-07-01 2024-01-04 Bristol-Myers Squibb Company Methods for antibody humanization
WO2024015993A1 (en) 2022-07-15 2024-01-18 Fibrogen, Inc. Modified anti-galectin-9 antibody and uses thereof
AR129991A1 (es) 2022-07-22 2024-10-23 Bristol Myers Squibb Co Anticuerpos que se unen a la pad4 humana y usos de los mismos
WO2024030956A2 (en) 2022-08-03 2024-02-08 Mozart Therapeutics, Inc. Cd39-specific binding agents and methods of using the same
JP2025525937A (ja) 2022-08-05 2025-08-07 ジュノー セラピューティクス インコーポレイテッド Ｇｐｒｃ５ｄおよびｂｃｍａに特異的なキメラ抗原受容体
KR20250052418A (ko) 2022-08-19 2025-04-18 피브로겐, 인크. 항-ccr8 항체 및 그의 용도
KR20250084921A (ko) 2022-08-26 2025-06-11 주노 쎄러퓨티크스 인코퍼레이티드 델타-유사 리간드 3 (dll3)에 특이적인 항체 및 키메라 항원 수용체
CN120077071A (zh) 2022-09-07 2025-05-30 当康生物技术有限责任公司 抗vista构建体及其用途
WO2024102948A1 (en) 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
JP2026500503A (ja) 2022-12-13 2026-01-07 ジュノー セラピューティクス インコーポレイテッド Ｂａｆｆ－ｒおよびｃｄ１９に特異的なキメラ抗原受容体、ならびにその方法および使用
WO2024216064A1 (en) 2023-04-14 2024-10-17 Twist Bioscience Corporation Compositions and methods related to dkk1 binders
CN121194993A (zh) 2023-05-24 2025-12-23 莫扎特治疗公司 Cd8特异性结合蛋白及其应用方法
WO2025038492A1 (en) 2023-08-11 2025-02-20 Abalytics Oncology, Inc. Anti-ctla-4 antibodies and related binding molecules and methods and uses thereof
WO2025048887A1 (en) 2023-09-01 2025-03-06 Inhibrx Biosciences, Inc. Ox40 agonist therapy
WO2025048860A1 (en) 2023-09-01 2025-03-06 Inhibrx Biosciences, Inc. Ox40 agonist therapy
TW202535954A (zh) 2023-09-26 2025-09-16 丹麥商珍美寶股份有限公司 Ｐｔｋ７結合劑、其共軛物及使用彼等之方法
WO2025085489A1 (en) 2023-10-17 2025-04-24 Bristol-Myers Squibb Company Gspt1-degrading compounds, anti-cd33 antibodies and antibody-drug conjugates and uses thereof
WO2025111402A1 (en) 2023-11-21 2025-05-30 Board Of Regents Of The University Of Nebraska Anti-amyloid beta antibodies and related compositions and methods thereof
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法
WO2025149661A1 (en) 2024-01-10 2025-07-17 Genmab A/S Slitrk6 binding agents, conjugates thereof and methods of using the same
WO2025174974A1 (en) 2024-02-14 2025-08-21 Bristol-Myers Squibb Company Anti-cd33 antibodies and uses thereof
WO2025184421A1 (en) 2024-02-28 2025-09-04 Juno Therapeutics, Inc. Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods
WO2025181219A1 (en) 2024-02-29 2025-09-04 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
WO2025199352A2 (en) 2024-03-20 2025-09-25 Juno Therapeutics, Inc. Antibodies specific for solute carrier family 34 member 2 (slc34a2)
WO2025222129A2 (en) 2024-04-19 2025-10-23 Mozart Therapeutics, Inc. Engineered cytokines and targeted cytokine delivery
US12509510B2 (en) 2024-04-23 2025-12-30 Attovia Therapeutics, Inc. IL31-binding polypeptides and uses thereof
WO2025240670A2 (en) 2024-05-15 2025-11-20 Abalytics Oncology, Inc. Anti-pd-1 antibodies and related binding molecules and methods and uses thereof
WO2025255405A1 (en) 2024-06-06 2025-12-11 Bristol-Myers Squibb Company Anti-fap antibodies and uses thereof
WO2025255349A1 (en) 2024-06-06 2025-12-11 Bristol-Myers Squibb Company Multispecific anti-cd40 / anti-fap antibodies and uses thereof
WO2025262564A1 (en) 2024-06-17 2025-12-26 Pfizer Inc. Use of anti-cxcr5 antibodies

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775622A (en) * 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
JPS63501765A (ja) * 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US6306625B1 (en) * 1988-12-30 2001-10-23 Smithkline Beecham Biologicals, Sa Method for obtaining expression of mixed polypeptide particles in yeast
US5545727A (en) * 1989-05-10 1996-08-13 Somatogen, Inc. DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin
WO1991002057A1 (en) 1989-08-09 1991-02-21 Delta Biotechnology Limited Polypeptide production in fungi
GB8927480D0 (en) 1989-12-05 1990-02-07 Delta Biotechnology Ltd Mutant fungal strain detection and new promoter
US5202422A (en) 1989-10-27 1993-04-13 The Scripps Research Institute Compositions containing plant-produced glycopolypeptide multimers, multimeric proteins and method of their use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ATE220105T1 (de) * 1991-04-01 2002-07-15 Merck & Co Inc Gene, die die proteolytische aktivitaet von pichia beeinflussen und deren verwendung
US5330901A (en) * 1991-04-26 1994-07-19 Research Corporation Technologies, Inc. Expression of human serum albumin in Pichia pastoris
US5440018A (en) * 1992-05-20 1995-08-08 The Green Cross Corporation Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same
DE69433279T2 (de) 1993-02-10 2004-07-15 Unilever N.V. Isolierungsverfahren verwendend immobilisierte proteine mit spezifischen bindungskapazitäten
AU6445894A (en) 1993-03-19 1994-10-11 Duke University Method of treatment of tumors with an antibody binding to tenascin
ES2251723T3 (es) 1994-08-12 2006-05-01 Immunomedics, Inc. Inmunoconjugados y anticuerpos humanizados especificos para linfoma de celulas b y celulas de leucemia.
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US6232111B1 (en) * 1996-04-10 2001-05-15 Merck & Co., Inc. Method for improving culture medium for recombinant yeast
WO2000023579A1 (en) * 1998-10-22 2000-04-27 The Regents Of The University Of California Functionally assembled antigen-specific intact recombinant antibody and a method for production thereof
US6258559B1 (en) * 1999-03-22 2001-07-10 Zymogenetics, Inc. Method for producing proteins in transformed Pichia
WO2003016525A1 (fr) 2001-08-16 2003-02-27 Kansai Chemical Engineering Co., Ltd. Procede de production d'alcool a partir d'amidon
AU2002332598A1 (en) 2001-08-22 2003-03-10 Shengfeng Li Compositions and methods for generating antigen-binding units
EP1438400B1 (en) 2001-10-01 2009-06-17 Dyax Corp. Multi-chain eukaryotic display vectors and uses thereof
CA2499467A1 (en) * 2002-09-20 2004-04-01 Cym1P A/S Methods for increasing the production of a recombinant polypeptide from a host cell

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9139825B2 (en) 2009-10-30 2015-09-22 Novartis Ag Universal fibronectin type III bottom-side binding domain libraries
US10253313B2 (en) 2009-10-30 2019-04-09 Novartis Ag Universal fibronectin type III bottom-side binding domain libraries

Also Published As

Publication number Publication date
EP1678314B1 (en) 2012-09-05
EP1678314A4 (en) 2007-03-07
JP2015062433A (ja) 2015-04-09
IL174783A0 (en) 2006-08-20
PL1678314T3 (pl) 2013-02-28
CA2541651A1 (en) 2005-05-06
CN1871359A (zh) 2006-11-29
US20160068849A1 (en) 2016-03-10
US8709756B2 (en) 2014-04-29
CN101979650A (zh) 2011-02-23
DK1678314T3 (da) 2012-12-03
DK2330201T3 (en) 2017-07-24
US7927863B2 (en) 2011-04-19
JP2012095669A (ja) 2012-05-24
CN101979650B (zh) 2015-09-16
US20200031949A1 (en) 2020-01-30
US20060270045A1 (en) 2006-11-30
US20140206039A1 (en) 2014-07-24
AU2009213095A1 (en) 2009-10-08
NZ547279A (en) 2008-04-30
SI1678314T1 (sl) 2013-01-31
JP4994038B2 (ja) 2012-08-08
PT1678314E (pt) 2012-11-27
IL211402A0 (en) 2011-04-28
ES2630224T3 (es) 2017-08-18
HUE033349T2 (en) 2017-11-28
AU2004283299B2 (en) 2009-06-18
US10155819B2 (en) 2018-12-18
US10259883B2 (en) 2019-04-16
IL174783A (en) 2012-10-31
WO2005040395A1 (en) 2005-05-06
CA2541651C (en) 2011-05-24
EP2330201B1 (en) 2017-04-05
US20160297887A9 (en) 2016-10-13
AU2004283299A1 (en) 2005-05-06
US20110183402A1 (en) 2011-07-28
US9873746B2 (en) 2018-01-23
EP2330201A1 (en) 2011-06-08
EP1678314A1 (en) 2006-07-12
US11447560B2 (en) 2022-09-20
CN1871359B (zh) 2010-11-17
ES2393555T3 (es) 2012-12-26
HK1093222A1 (en) 2007-02-23
US20080003643A1 (en) 2008-01-03
JP5982504B2 (ja) 2016-08-31
AU2009213095B2 (en) 2012-01-19
US8268582B2 (en) 2012-09-18
JP2007508847A (ja) 2007-04-12
US20130029880A1 (en) 2013-01-31
IL211402A (en) 2015-08-31

Similar Documents

Publication Publication Date Title
NO20062134L (no) Fremgangsmater for syntetisering av heteromultimere polypeptider i gjaer ved anvendelse av haploid parrings strategi
EP2351834A3 (en) Production of biologically active proteins
NO973848D0 (no) Fremgangsmåte til fremstilling av hemoglobinliknende protein
IL184112A0 (en) A method for producing polypeptides or proteins in a disulfide-bridged two-chain form
IL190705A0 (en) A method for the production of a permanent human cell line
NO2012001I1 (no) Ipilimumab (INN) - krav i basispatent
DE60336228D1 (de) Verfahren zur gleichzeitigen herstellung von multiplen proteinen; vektoren und zellen, die hierfür verwendung finden
ATE175446T1 (de) Immunogene peptide, antikörper sowie deren verwendungen im zusammenhang mit der cd4- rezeptorbindung
MX2022004316A (es) Composiciones y metodos para sintesis in vivo de polipeptidos no naturales.
GB2451928A (en) Modified diphtheria toxins
WO2006069403A3 (en) Methods for producing soluble multi-membrane-spanning proteins
TW200732472A (en) Method for the recombinant expression of a polypeptide
ATE112687T1 (de) Mutanten des hiv-1 hüllproteins mit fehlenden hypervariabelen domänen.
WO2004050859A3 (en) Homologous recombination in multipotent adult progenitor cells
WO2021194826A3 (en) Recombinant sars-cov-2 spike protein and uses thereof
WO2005086667A3 (en) High efficiency peptide production in plant cells
DK1137808T3 (da) Fremgangsmåde til fremstilling af rekombinante celler
MX2023002413A (es) Proteinas de fusion inmunogenicas de coronavirus y metodos relacionados.
WO2004111194A3 (en) Method to increase protein production in culture
EP4421180A3 (en) Compositions comprising nkg2d, cxcr2, and dap10/dap12 fusion polypeptides and methods of use thereof
WO2004033627A3 (en) Methods for efficient production of mammalian recombinant proteins
WO2006124013A3 (en) Novel stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof, and method of use
WO2023141478A3 (en) Cytokine-immunoreceptor fusion proteins and uses thereof
WO2020232017A3 (en) Expression of modified proteins in a peroxisome
WO2018081448A8 (en) Modified immunoglobulin hinge regions to reduce hemagglutination

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application